Pluristem Therapeutics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pluristem Therapeutics

PSTI 8.720

+0.2%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: xcentral1	12/15/2009 10:25:37 AM
	of 295

Data Safety Monitoring Board (DSMB) Approves Advancement to Intermediate Dose Level of PLX-PAD HAIFA, Israel, Dec 15, 2009 (BUSINESS WIRE) -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that the independent DSMB approved the advancement to the intermediate dose level of the company's placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD). "The advancement to the next dose level with Pluristem's placenta derived PLX-PAD is encouraging and we hope that the positive trend in clinical results derived from treating the first patients at the lower dose will continue," said Professor Dr. Andre Schmidt-Lucke, director of the Franziskus-Krankenhaus of Berlin and Project Leader of the PLX-PAD clinical trial in Europe. Zami Aberman, chairman and CEO of Pluristem, added, "The DSMB approval confirms the safety profile of the first dose of PLX-PAD. We hope that the administration of the intermediate dose level will provide further evidence that PLX-PAD is potentially a safe and effective treatment option for patients with CLI." This Phase I study is designed to evaluate the safety of PLX-PAD on three dose levels in patients diagnosed with CLI. A total of up to 15 adults with the disease will be included in this dose escalating trial.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next